Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Experts discuss current and potential future shortages affecting the oncology field as well as strategies for preventing and managing shortages.
Cancer patients have voiced concerns about a lack of masking at cancer centers and have reported being harassed for wearing masks in public.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Growing evidence suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine.
Women in academic medicine typically have lower starting salaries than men, and this disparity remains after 10 years on the job.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
An update to active surveillance recommendations has some physicians concerned.
About 20% of pediatric cancer patients who developed COVID-19 had severe or critical disease.
